Dr Toni Choueiri speaks to ecancer about his keynote lecture at the virtual ENA 2020 about VHL/HIF (and VEGF) inhibitors in renal cancer at the ENA virtual meeting 2020.
He starts with explaining the role of VHL/HIF and VEGF inhibitors in clear cell renal cell carcinoma. Then he talks of the main points his lecture aimed at and how important it was that another biomarker was being used for targeted therapy.
He says before we were using cytokine inhibitors but now VHL/HIF inhibitors can also be used which will open new avenues for translational research.
Dr Choueiri finishes it by stating how these new developments can affect the future of clear cell renal cell carcinoma treatment.